Newtyn Management, LLC Kodiak Sciences Inc. Transaction History

Newtyn Management, LLC

$567 Million
Q3 2024

A detailed history of Newtyn Management, LLC transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Newtyn Management, LLC holds 740,505 shares of KOD stock, worth $6.48 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares

740,505

Previous 930,000 20.38%

Holding current value

$6.48 Million

Previous $2.19 Million 11.58%

% of portfolio

0.34%

Previous 0.48%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.2 - $3.25 $416,889 - $615,858	-189,495 Reduced 20.38%	740,505 $1.93 Million
Q2 2024 Aug 14, 2024	SELL	$2.29 - $4.48 $160,300 - $313,600	-70,000 Reduced 7.0%	930,000 $2.19 Million
Q1 2024 May 15, 2024	SELL	$3.01 - $7.45 $2.32 Million - $5.75 Million	-771,241 Reduced 43.54%	1,000,000 $5.26 Million
Q4 2023 Feb 14, 2024	BUY	$1.4 - $3.24 $227,565 - $526,652	162,547 Added 10.1%	1,771,241 $5.38 Million
Q3 2023 Nov 14, 2023	BUY	$1.8 - $7.49 $1.11 Million - $4.64 Million	618,991 Added 62.54%	1,608,694 $2.9 Million
Q2 2023 Aug 14, 2023	BUY	$4.3 - $9.48 $416,962 - $919,256	96,968 Added 10.86%	989,703 $6.83 Million
Q1 2023 May 15, 2023	BUY	$4.81 - $8.88 $446,055 - $823,486	92,735 Added 11.59%	892,735 $5.53 Million
Q4 2022 Feb 14, 2023	BUY	$6.52 - $8.05 $815,000 - $1.01 Million	125,000 Added 18.52%	800,000 $5.73 Million
Q3 2022 Nov 14, 2022	SELL	$7.57 - $12.5 $378,500 - $625,000	-50,000 Reduced 6.9%	675,000 $5.23 Million
Q2 2022 Aug 15, 2022	BUY	$5.04 - $9.48 $3.65 Million - $6.87 Million	725,000 New	725,000 $5.54 Million

Others Institutions Holding KOD

# of Institutions

Shares Held

39M

Call Options Held

6.5K

Put Options Held

5.8K

View Full List

About Kodiak Sciences Inc.

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

More about KOD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Newtyn Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Newtyn Management, LLC with notifications on news.

Account

Newtyn Management, LLC Kodiak Sciences Inc. Transaction History